Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NTRK fusions in colorectal cancer: clinical meaning and future perspective.
Ratti M, Grizzi G, Passalacqua R, Lampis A, Cereatti F, Grassia R, Hahne JC. Ratti M, et al. Among authors: passalacqua r. Expert Opin Ther Targets. 2021 Aug;25(8):677-683. doi: 10.1080/14728222.2021.1978070. Epub 2021 Sep 16. Expert Opin Ther Targets. 2021. PMID: 34488530 Review.
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; Italian Trials in Medical Oncology Group. Di Bartolomeo M, et al. Among authors: passalacqua r. Target Oncol. 2014 Jun;9(2):155-62. doi: 10.1007/s11523-013-0283-8. Epub 2013 Jul 3. Target Oncol. 2014. PMID: 23821376 Clinical Trial.
Clinical development of mTor inhibitors for renal cancer.
Ghidini M, Petrelli F, Ghidini A, Tomasello G, Hahne JC, Passalacqua R, Barni S. Ghidini M, et al. Among authors: passalacqua r. Expert Opin Investig Drugs. 2017 Nov;26(11):1229-1237. doi: 10.1080/13543784.2017.1384813. Epub 2017 Oct 3. Expert Opin Investig Drugs. 2017. PMID: 28952411 Review.
First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study.
Tomasello G, Valeri N, Ghidini M, Smyth EC, Liguigli W, Toppo L, Mattioli R, Curti A, Hahne JC, Negri FM, Panni S, Ratti M, Lazzarelli S, Gerevini F, Colombi C, Panni A, Rovatti M, Treccani L, Martinotti M, Passalacqua R. Tomasello G, et al. Among authors: passalacqua r. Oncotarget. 2017 Dec 4;8(67):111795-111806. doi: 10.18632/oncotarget.22909. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340092 Free PMC article.
172 results